Table 1.
Therapy profiles
| Therapy profiles | |||
|---|---|---|---|
| Compounds | N | Duration | # Previous |
| 3TC AZT | 259 | 549 (21,3515) | 3 (0,28) |
| d4T DDI | 149 | 553 (40,3291) | 5.2 (0,19) |
| TDF FTC | 123 | 284 (28,1122) | 5.9 (0,25) |
| 3TC d4T | 115 | 646 (19,3508) | 4.5 (0,18) |
| 3TC TDF | 96 | 311 (27,1360) | 7.4 (0,20) |
| 3TC DDI | 61 | 590 (43,2268) | 8.6 (1,37) |
| 3TC ABC | 52 | 397 (40,1140) | 6.5 (0,18) |
| AZT | 50 | 379 (1,1939) | 2 (0,12) |
| 3TC ABC AZT | 50 | 437 (28,1423) | 4.6 (0,19) |
| AZT DDI | 49 | 413 (57,1408) | 5.1 (0,17) |
The data in the current study contains 119 unique combinations of reverse transcriptease inhibitors. The 10 most common combinations are listed here, along with the number of subjects receiving them, mean (range) duration in days, and mean (range) number of previous therapies when administered. Note that these therapies may also have included protease inhibitors. The full table is given in the supplement.